Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126924511 | 12692451 | 1 | I | 201510 | 20151028 | 20160829 | 20160829 | EXP | CA-ROCHE-1652998 | ROCHE | 57.00 | YR | F | Y | 0.00000 | 20160829 | MD | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126924511 | 12692451 | 1 | PS | RITUXAN | RITUXIMAB | 1 | Intravenous (not otherwise specified) | U | 103705 | 1000 | MG | SOLUTION FOR INFUSION | |||||||
| 126924511 | 12692451 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Intravenous (not otherwise specified) | U | 125276 | 8 | MG/KG | SOLUTION FOR INFUSION | |||||||
| 126924511 | 12692451 | 3 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Oral | 0 | |||||||||||
| 126924511 | 12692451 | 4 | SS | ARAVA | LEFLUNOMIDE | 1 | Oral | AS NEEDED | 0 | 20 | MG | QD | |||||||
| 126924511 | 12692451 | 5 | SS | METHOTREXATE SODIUM. | METHOTREXATE SODIUM | 1 | Oral | 0 | 10 | MG | /wk | ||||||||
| 126924511 | 12692451 | 6 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Oral | 0 | TABLET | ||||||||||
| 126924511 | 12692451 | 7 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | 0 | 3 | MG/KG | |||||||||
| 126924511 | 12692451 | 8 | C | VITAMIN C | ASCORBIC ACID | 1 | 0 | ||||||||||||
| 126924511 | 12692451 | 9 | C | CORTISONE | CORTISONEHYDROCORTISONE | 1 | 0 | ||||||||||||
| 126924511 | 12692451 | 10 | C | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 0 | 5 | MG | BID | ||||||||
| 126924511 | 12692451 | 11 | C | ROSUVASTATIN. | ROSUVASTATIN | 1 | 0 | ||||||||||||
| 126924511 | 12692451 | 12 | C | BETAHISTAMINE | 2 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126924511 | 12692451 | 1 | Rheumatoid arthritis |
| 126924511 | 12692451 | 2 | Product used for unknown indication |
| 126924511 | 12692451 | 3 | Rheumatoid arthritis |
| 126924511 | 12692451 | 4 | Rheumatoid arthritis |
| 126924511 | 12692451 | 5 | Rheumatoid arthritis |
| 126924511 | 12692451 | 6 | Rheumatoid arthritis |
| 126924511 | 12692451 | 7 | Rheumatoid arthritis |
| 126924511 | 12692451 | 10 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126924511 | 12692451 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126924511 | 12692451 | Blood creatine phosphokinase increased | |
| 126924511 | 12692451 | Condition aggravated | |
| 126924511 | 12692451 | Drug ineffective | |
| 126924511 | 12692451 | Haematemesis | |
| 126924511 | 12692451 | Hepatotoxicity | |
| 126924511 | 12692451 | Joint swelling | |
| 126924511 | 12692451 | Nausea | |
| 126924511 | 12692451 | Platelet count increased | |
| 126924511 | 12692451 | Vitamin D decreased | |
| 126924511 | 12692451 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126924511 | 12692451 | 1 | 2012 | 2015 | 0 | |
| 126924511 | 12692451 | 2 | 20111026 | 2012 | 0 | |
| 126924511 | 12692451 | 4 | 20080916 | 20091022 | 0 | |
| 126924511 | 12692451 | 5 | 20080916 | 20091022 | 0 | |
| 126924511 | 12692451 | 7 | 20090625 | 20091022 | 0 | |
| 126924511 | 12692451 | 10 | 20151106 | 0 |